

FORM PTO-1449  
(REV. 7-80)

ATTY. DOCKET NO.

SERIAL NO.

INFORMATION DISCLOSURE CITATION  
IN AN APPLICATION

(Use several sheets if necessary)

KIR92-01A4

08/690,775

APPLICANTS

Marc Feldmann and Ravinder N.  
Maini

FILING DATE

August 01, 1996

GROUP

1208 +806 1644

## U.S. PATENT DOCUMENTS

EXAM- INER INI- TIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE IF APPROPRIATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

## FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION YES NO
M6	AL	WO 89/08460	21-SEP-89	PCT			
	AM	WO 92/08474	29-MAY-92	PCT			
	AN	WO 92/07585	14-MAY-92	PCT			
	AO						
	AP						
	AQ						

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

AR	Horneff, G., et al., "Elevated levels of circulating tumor necrosis factor- $\alpha$ , interferon- $\gamma$ , and interleukin-2 in systemic reactions induced by anti-CD4 therapy in patients with rheumatoid arthritis", <i>Cytokine</i> , 3(3):266-247 (1991).
AS	Brennan, F., et al., "Inhibitory effect of TNF $\alpha$ antibodies on synovial cell interleukin-1 production in rheumatoid arthritis", <i>The Lancet</i> , 2(8657):244-247 (1989).
AT	Steinbruchel, D., et al., "Monoclonal antibody treatment (anti-CD4 and anti-interleukin-2 receptor) combined with cyclosporin A has a positive but not simple dose-dependent effect on rat renal allograft survival", <i>Scandinavian J. Immunol.</i> , 34(5):627-633 (1991).

EXAMINER

PHILIP GAMMEL

DATE CONSIDERED

2/3/97

FORM PTO-1449  
(REV. 7-80)INFORMATION DISCLOSURE CITATION  
IN AN APPLICATION

(Use several sheets if necessary)

ATTY. DOCKET NO.

KIR92-01A4

SERIAL NO.

08/690,775

APPLICANTS

Marc Feldmann and Ravinder N.  
Maini

FILING DATE

August 01, 1996

GROUP

1208

1644

1806

U.S. PATENT DOCUMENTS

EXAM- INER INI- TIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE IF APPROPRIATE




## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

M-	AU	Breedveld, F., et al., "Anti-CD4 antibodies in rheumatoid arthritis", <i>Clinical and Experimental Rheumatology</i> , 10(4):325-326 (1992).
✓	AV	Brennan, F., et al., "TNF $\alpha$ -a pivotal role in rheumatoid arthritis?", <i>British J. Rheumatology</i> , 31(5):293-298 (1992).
✓	AW	Elliott, M.J., et al., "Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to TNF- $\alpha$ : safety, clinical efficacy and control of the acute phase response", <i>Cell. Biochemistry, Supplement</i> , 0(17B):145 (1993); Abstract EZ405.
	AX	Williams, R.O., et al., "Synergy between anti-CD4 and anti-tumor necrosis factor in the amelioration of established collagen-induced arthritis", <i>Proc. Natl. Acad. Sci. USA</i> , 91:2762-2766 (1994).
-	AY	Ralph, P., "Clinical and Preclinical Studies Presented at the Keystone Symposium on Arthritis, Related Diseases, and Cytokines," <i>Lymphokine and Cytokine Research.</i> , 12(4):261-263 (1993).
-	AZ	Racadot, E., "Immunological follow-up of 17 patients with rheumatoid arthritis treated in vivo with an anti-T CD4+ monoclonal antibody (B-F5)," <i>Clinical and Experimental Rheumatology</i> , 10:365-374 (1992).
-	AR2	Williams, R.O., et al., "Successful therapy of collagen-induced arthritis with TNF receptor-IgG fusion protein and combination with anti-CD4," <i>Immunology</i> , 84:433-439 (March 1995).
M	AS2	Van Der Lubbe, P.A., et al., "A Randomized, Double-Blind, Placebo-Controlled Study of CD4 Monoclonal Antibody Therapy In Early Rheumatoid Arthritis," <i>Arth. Rheum.</i> , 38(8):1097-1106 (1995).

EXAMINER

DATE CONSIDERED

2/3/97

FORM PTO-1449 (REV. 7-80) INFORMATION DISCLOSURE CITATION IN AN APPLICATION  (Use several sheets if necessary)				ATTY. DOCKET NO. KIR92-01A4		SERIAL NO. 08/690,775	
APPLICANTS: Marc Feldmann and Ravinder N. Maini				FILING DATE August 01, 1996		GROUP 1208 <sup>(644)</sup> <del>1305</del>	
U.S. PATENT DOCUMENTS							
EXAM- INER INI- TIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE IF APPROPRIATE
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)							
	AT2	Choy, E.H.S., et al., "Therapeutic Monoclonal Antibodies," <i>British J. Rheumatology</i> , 34:707-715 (1995).					
	AU2	Rankin, E.C.C., et al., "The Therapeutic Effects of an Engineered Human Anti-Tumour Necrosis Factor Alpha Antibody (CDP571) in Rheumatoid Arthritis," <i>British J. Rheumatology</i> , 34:334-342 (1995).					
	AV2	Butler, D.M., et al., "Modulation of proinflammatory cytokine release in rheumatoid synovial membrane cell cultures. Comparison of monoclonal anti TNF- $\alpha$ antibody with the interleukin-1 receptor antagonist," <i>Eur. Cytokine Netw.</i> , 6(4):225-230 (1995).					
	AW2	Horneff, G., et al., "Treatment of Rheumatoid Arthritis with an Anti-CD4 Monoclonal Antibody," <i>Arthritis &amp; Rheumatism</i> , 34(2): 129-140 (1991).					
	AX2	Van Dulleman, H.M., et al., "Treatment of Crohn's Disease With Anti-Tumor Necrosis Factor Chimeric Monoclonal Antibody (cA2)," <i>Gastroenterology</i> , 109(1):129-135 (1995).					
	AY2	Watts, R.A., and Isaacs, J.D., "Immunotherapy of rheumatoid arthritis," <i>Annals Rheumatic Diseases</i> , 51:577-579 (1992).					
	AZ2	Schacht, E., "Gegenwärtige und zukünftige Therapiestrategien der rheumatoiden Arthritis (RA)," ["The current and future therapy strategies of rheumatoid arthritis (RA)"], <i>Zeitschrift für Rheumatologie</i> , 52(6):365-382 (1993).					
EXAMINER  PHILIP GAMBEL				DATE CONSIDERED  2/3/97			

FORM PTO-1449 (REV. 7-80)		ATTY. DOCKET NO. KIR92-01A4		SERIAL NO. 08/690,775	
INFORMATION DISCLOSURE CITATION IN AN APPLICATION (Use several sheets if necessary)		APPLICANTS Marc Feldmann and Ravinder N. Maini			
FILING DATE August 01, 1996		GROUP 1208 <sup>1644</sup> <del>1806</del>			
U.S. PATENT DOCUMENTS					
EXAM- INER INI- TIAL		DOCUMENT NUMBER	DATE	NAME	CLASS
FOREIGN PATENT DOCUMENTS					
		DOCUMENT NUMBER	DATE	COUNTRY	CLASS
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)					
M6	AR3	Elliott, M.J., et al., "Treatment of Rheumatoid Arthritis with Chimeric Monoclonal Antibodies to TNF $\alpha$ ", <i>Rev. Esp. Reumatol</i> , 20 Suppl. 1:148 (1993); Abstract 320.			
	AS3	Elliott, M.J., et al., "Treatment of Rheumatoid Arthritis with Chimeric Monoclonal Antibodies to Tumor Necrosis Factor $\alpha$ ", <i>Arth. Rheum.</i> , 36(12):1681-1690 (1993).			
	AT3	Elliott, M.J., et al., "Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor $\alpha$ (CA2) versus placebo in rheumatoid arthritis", <i>The Lancet</i> 344:1105-1110 (1994).			
	AU3	Elliott, M.J., et al., "Repeated therapy with monoclonal antibody to tumour necrosis factor $\alpha$ (CA2) in patients with rheumatoid arthritis", <i>The Lancet</i> 344:1125-1127 (1994).			
	AV3	Maini, R.N., et al., "Clinical response of rheumatoid arthritis (RA) to anti-TNF $\alpha$ (CA2) monoclonal antibody (mab) is related to administered dose and persistence of circulating antibody", <i>Arth. Rheum. Supplement</i> , 38(9):S186 (1995); Abstract 200.			
M	AW3	Maini, R.N., "The role of cytokines in rheumatoid arthritis", <i>J. Royal College of Physicians of London</i> , 30(4):344-351 (1996).			
EXAMINER Philip Gammagl			DATE CONSIDERED 2/3/97		